Yuan Da Pharmaceutical: Innovative core drug approved to join international multicenter Phase III clinical trial.

On July 22nd, Yuan Da Pharmaceutical announced that the application for the global innovative radiopharmaceutical TLX591, used for the treatment of prostate cancer, to join the international multicenter Phase III clinical trial has received an implicit permit from the National Medical Products Administration. This study plans to enroll more than 500 patients in China, the United States, Australia, New Zealand, Europe, and other regions globally, aiming to evaluate the efficacy and safety of TLX591 in combination with standard treatment compared to standard treatment alone in patients with metastatic castration-resistant prostate cancer who have previously received treatment with androgen receptor pathway inhibitors.